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Abstract
Background: Telomerase is a ribonucleoprotein enzyme that synthesises telomeres after cell
division and maintains chromosomal length and stability thus leading to cellular immortalisation.
The hTERT (human telomerase reverse transcriptase) subunit seems to be the rate-limiting
determinant of telomerase and knowledge of factors controlling hTERT transcription may be useful
in therapeutic strategies. The hTERT promoter contains binding sites for c-Myc and there is some
experimental and in vitro evidence that c-Myc may increase hTERT expression. We previously
reported no correlation between c-Myc mRNA expression and hTERT mRNA or telomerase
activity in human breast cancer. This study aims to examine the correlation between hTERT
expression as determined by immunohistochemistry and c-Myc expression, lymph node status, and
tumour size and grade in human breast cancer.
Materials and methods: The immunohistochemical expression of hTERT and c-Myc was
investigated in 38 malignant breast tumours. The expression of hTERT was then correlated with
the lymph node status, c-Myc expression and other clinicopathological parameters of the tumours.
Results: hTERT expression was positive in 27 (71%) of the 38 tumours. 15 (79%) of 19 node
positive tumours were hTERT positive compared with 11 (63%) of 19 node negative tumours. The
expression was higher in node positive tumours but this failed to reach statistical significance (p =
0.388). There was no significant association with tumour size, tumour grade or c-Myc expression.
However, hTERT expression correlated positively with patients' age (correlation coefficient =
0.415, p = 0.0097).
Conclusion: hTERT protein expression is independent of lymph node status, tumour size and
grade and c-Myc protein expression in human breast cancer
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Introduction
Telomeres are highly specialised structures at the end of
each chromosome which contain tandem repeat DNA
sequences? In humans, this sequence is TTAGGG [1].
According to the telomere/telomerase hypothesis, the tel-
omeric ends of chromosomes of normal somatic cells rep-
licate inefficiently and progressively shorten at each cell
division until cumulative loss impairs vital cellular func-
tions and the cells exit the cell cycle and undergo apopto-
sis [2].
Telomerase is a ribonucleoprotein enzyme that contains
an RNA template complementary to the (TTAGGG) n
repeats and thus synthesises telomeres after cell division
and maintains chromosomal length and stability leading
to immortalisation [3-6]. Accordingly, telomerase activity
has been investigated and detected in a wide range of
human malignancies, germline cells and immortal cells
but not in normal somatic cells [3-8]. Human telomerase
consists of an RNA subunit – human telomerase RNA
(hTR) [9], a protein component (human telomerase asso-
ciated protein 1 – hTEP1) [10] and the catalytic subunit
hTERT (human telomerase reverse transcriptase) [11-13].
Of these subunits telomerase activity requires the presence
of hTR, which is the RNA template for the telomeric
repeat, and hTERT, which is the reverse transcriptase. The
gene coding for hTERT has been cloned and mapped to
5p15.33 [14]. hTERT is a 127-kDa protein whose function
closely correlates with telomerase activity [10,15,16].
Investigation of the mechanisms of hTERT control is
important in elucidating the pathways that may be ame-
nable to therapeutic manipulation and one such pathway
involves the transcription factor Myc.
An increased level of c-Myc occurs frequently in a wide
range of tumours [17-23] due to de-regulated expression
of myc through gene amplification, retroviral insertion or
chromosomal translocation. Sequence analysis of the
hTERT gene promoter has shown the presence of at least 2
and perhaps as many as 29 E boxes [24], potential binding
sites for the Myc oncoprotein, and the possibility of a reg-
ulatory role for Myc has been explored in a number of
studies. It has been found that purified Myc interacts with
the E box sequences and that cotransfection of Myc
induces activity in the isolated hTERT promoter [25]. It
has been shown that retroviral expression of c-myc
increases the amount of hTERT mRNA in human mam-
mary epithelial cells and fibroblasts and telomerase activ-
ity could thereafter be detected [26]. It has also been
reported that expression of c-Myc leads to increased
hTERT expression and telomerase activity in human B
cells [27]. Moreover, since this does not require protein
synthesis this appears to be due to a direct effect of Myc on
the hTERT promoter and not secondary to an increase in
cellular proliferation by Myc [27]. In addition, the intro-
duction of Myc anti-sense RNA has been shown to lead to
a reduction in hTERT promoter activity [25]. Latil et al
[28] demonstrated a relationship between hTERT and c-
Myc expressions in prostate cancer whilst other investiga-
tors [29] have found that Mad1, another member of Myc
pathway, is a suppressor of hTERT at the level of
transcription.
Using RT-PCR, we found that hTERT mRNA expression
was significantly higher in breast cancer tissues compared
with non-cancerous breast tissues [30]. However, we did
not observe any relationship between hTERT expression
and tumour stage, patients' age or c-Myc expression. Due
to the potential limitations of mRNA studies which we
highlighted in our previous report, we planned to deter-
mine the protein expression of both hTERT and c-Myc
using immunohistochemistry (IHC) and investigate any
potential associations.
The aim of this study was to determine the (IHC) expres-
sion of hTERT in human breast cancer and to examine the
association between hTERT expression and clinicopatho-
logical parameters of the tumours (size, grade, and nodal
status) and c-Myc expression.
Methods
Institutional guidelines including ethical approval were
followed. Patients were treated with wide local excision or
mastectomy and axillary node dissection. Patients with
estrogen and /or progesterone positive tumours received
tamoxifen. Radiotherapy was administered to all patients
who had breast conserving surgery and chemotherapy to
patients with lymph node positive or high grade tumours.
Using IHC, the expressions of hTERT and c-Myc were
determined in 38 breast cancer specimens (19 specimens
were lymph node positive tumours and 19 were lymph
node negative tumours the specimens).
Immunohistochemistry
Staining
Paraffin sections were dewaxed in xylene (two changes
each for 5 minutes). Endogenous peroxidase was blocked
in 480 ml of Methanol and 6 ml of H2O2 for 15 minutes
and rinsed in running tap water for 5 minutes. Heat medi-
ated antigen retrival was performed as follows: 1 litre of
pH6 Citrate buffer was placed in the microwave into the
pressure cooker, then heated on full power for 10
minutes.
Sections were placed into the boiling buffer. Pressure
cooker was heated on full power until the pressure is
attained and then cooked for a further 2 minutes. Sections
were then rinsed well in running tap water and placed in
Tris Buffer. Primary antibody preparations were appliedJournal of Carcinogenesis 2005, 4:17 http://www.carcinogenesis.com/content/4/1/17
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and incubated for 45 minutes then washed in TRIS Buffer
(pH 7.6). The antibodies used are: NCLL-hTERT (Clone
44F12, 1:50 dilution, Novocastra Laboratories Ltd, New-
castle upon Tyne, UK) and NCL-cMYC (Clone 9E11,
1:200 dilution, Novocastra Laboratories Ltd, Newcastle-
upon-Tyne, UK). 5% goat serum was used for dilution.
Super enhancer was then applied for 20 minutes. Sections
were washed in TRIS Buffer (pH 7.6). Poly-HRP was then
applied for 30 minutes. Sections were washed in TRIS
Buffer (pH 7.6). DAB solution was then applied for 10
minutes. Slides were washed in distilled water, bleached
to de-activate the DAB and rinsed in running tap water.
Sections were then counterstained with Harris
Haematoxylin.
Evaluation of immunohistochemical staining
Two observers assessed the sections using the following
criteria:
hTERT
Scores were assigned as follows: 2, strong staining
throughout nucleus (Fig 1); 1, moderate staining of
nucleus or dotted staining of nucleolus (Fig 2); 0, no
staining.
c-Myc
Cytoplasmic staining intensity was graded as: no staining
(0), weak (1), moderate (2) (Fig 3), or strong (3) (Fig 4).
The percentage of tumour cells with c-Myc staining was
scored as follows: 1, <5%; 2, 5–20%; 3, 21–50%; 4, >50%.
Then the multiplication values were grouped into four
scores as 0, (multiplication values 0, 1); 1, (multiplication
values 2, 3); 2, (multiplication values 4, 6); or 3, (multi-
plication values 8, 9, 12).
Statistical analysis
Chi Square test was used to study the relationship
between hTERT expression in lymph node positive and
lymph node negative tumours. The expression of hTERT
in tumours was then correlated with c-Myc expression,
clinicopathological parameters of the tumours (size and
grade) and patients' age. A p-value of < 0.05 was consid-
ered statistically significant.
Results
hTERT expression was positive in 27 (71%) of 38
tumours. 15 (79%) of the 19 node positive tumours were
hTERT positive compared with 11 (63%) of the node neg-
ative tumours. Although hTERT expression was higher in
node positive tumours (median score 1.0 Vs 0), however
this failed to reach statistical significance (p = 0.388).
There was no significant correlation with tumour size,
tumour grade, hormone receptor status or c-Myc expres-
sion. Interestingly, hTERT expression correlated positively
with patients' age (correlation coefficient = 0.415, p =
0.0097). Table 1 demonstrates hTERT and c-Myc expres-
sion and the clinicopathological characteristics of the
tumours studied.
Discussion
Our observation that hTERT protein is expressed in most
breast tumours is expected and consistent with our previ-
ous reports using mRNA and enzyme measurements [30-
32]. The lack of is correlation between hTERT protein
Invasive ductal carcinoma – hTERT positive: 2 (strong  nuclear staining) Figure 1
Invasive ductal carcinoma – hTERT positive: 2 (strong 
nuclear staining).
Invasive ductal carcinoma – hTERT positive: 1 (moderate  nuclear staining of tumour cells and strong staining of sur- rounding lymphocytes Figure 2
Invasive ductal carcinoma – hTERT positive: 1 (moderate 
nuclear staining of tumour cells and strong staining of sur-
rounding lymphocytes.Journal of Carcinogenesis 2005, 4:17 http://www.carcinogenesis.com/content/4/1/17
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expression and tumour size, grade or nodal status is also
consistent with our previous study using mRNA and RT-
PCR technology [30]. However we previously reported
that telomerase activity correlated with these clinico-
pathological parameters [31,32]. Although hTERT expres-
sion is associated with malignancy, it does not seem to
correlate with tumour stage. This is probably a true obser-
vation as it has been demonstrated using both RT- PCR
and immunohistochemistry and could be explained on
the basis of post-transcriptional modification.
Bieche et al [33] reported a positive correlation between
hTERT and c-Myc gene expression. Furthermore, other
investigators [34-36] demonstrated that hTERT gene is a
direct target of c-Myc. Although the hTERT promoter con-
tains E-boxes, consistent with the findings of the present
study, we previously observed no correlation between c-
Myc mRNA levels and telomerase activity [37] and no
association between hTERT and c-Myc at the mRNA level
[30]. The control of hTERT is undoubtedly a complex one
and it is likely that a number of other transcription factors
influence its expression than c-Myc. These might act
together with c-Myc, as has been shown for Sp1 [38] or
independently. In this respect, it has been shown that
transfer of a normal chromosome 3 into human breast
carcinoma cells results in abolition of hTERT transcripts
without any change in c-Myc levels [39]. Furthermore, it is
known that another member of the Myc family, Mad1
forms a complex with Max and acts as a transcriptional
repressor at the same binding sites as Myc-Max. It has
been shown that, the proportion of Mad1 binding to the
hTERT promoter rises and that of Myc falls, during the dif-
ferentiation of HL60 cells [37,40]. This is associated with
reduced acetylation of the hTERT promoter and measure-
ment of the Mad/Myc ratio is likely to be important in
establishing the overall level of transcriptional activation
of hTERT.
Abbreviations
Int: c-Myc intensity
%: c-Myc percentage positive
Multip: c-Myc multiplication
Final: Final c-Myc score
Hist: Histology
D: ductal
L: Lobular
DL: Ductal and Lobular
P: Papillary
M: Mucoid
A: Apocrine
T: Tubular
LN: Lymph node status, P: positive, N: negative
ER: Oestrogen receptor status, P: positive, N: negative
Invasive ductal carcinoma – c-Myc positive: 2 (moderate  cytoplasmic staining) Figure 3
Invasive ductal carcinoma – c-Myc positive: 2 (moderate 
cytoplasmic staining).
Invasive ductal carcinoma – c-Myc positive: 3 (strong cyto- plasmic staining) Figure 4
Invasive ductal carcinoma – c-Myc positive: 3 (strong cyto-
plasmic staining).Journal of Carcinogenesis 2005, 4:17 http://www.carcinogenesis.com/content/4/1/17
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